Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby Maher

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
European Respiratory Review : an Official Journal of the European Respiratory Society|March 2, 2015
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosisVincent Cottin, Toby Maher
BMJ Open Respiratory Research|May 22, 2025
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosisToby Maher, Jin Woo Song, Mordechai Reuven Kramer, et al.
BMJ Open Respiratory Research|January 20, 2026
Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS studyFasihul Khan, Iain Stewart, Lucy Howard, et al.
Research Square|February 12, 2026
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisJustin Oldham, Philip Molyneaux, Manoj Maddali, et al.
Rheumatology (Oxford, England)|September 29, 2022
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive diseaseDavid Roofeh, Kevin K Brown, Ella A Kazerooni, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
European Respiratory Review : an Official Journal of the European Respiratory Society|March 2, 2015
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosisVincent Cottin, Toby Maher
BMJ Open Respiratory Research|May 22, 2025
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosisToby Maher, Jin Woo Song, Mordechai Reuven Kramer, et al.
BMJ Open Respiratory Research|January 20, 2026
Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS studyFasihul Khan, Iain Stewart, Lucy Howard, et al.
Research Square|February 12, 2026
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisJustin Oldham, Philip Molyneaux, Manoj Maddali, et al.
Rheumatology (Oxford, England)|September 29, 2022
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive diseaseDavid Roofeh, Kevin K Brown, Ella A Kazerooni, et al.
Pageof 1